INCOR Group buys stake in Renovis Pharma to form a new JV

Hyderabad based conglomerate INCOR Group and Renovis Labs, promoted by Prof. Javed Iqbal - country’s esteemed scientist, have entered into a new JV ‘INCOR Renovis’...

Pharma firm Cipla to invest Rs 26 crore in GoApptiv to raise stake to 22 pc

Pharma firm Cipla has agreed to acquire an additional stake for nearly Rs 26 crore in digital tech company GoApptiv Private to raise its shareholding to 22.02 per cent, the company said....

AstraZeneca gets EU support for targeted breast cancer therapies

AstraZeneca said two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the firm’s oncology portfolio...

NTAGI to examine trial data on SII's qHPV vaccine against cervical cancer

The government advisory panel NTAGI is likely to review on June 28 trial data on India's first quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, developed by the Serum Institute, official sources said on Sunday...

Pharmaceutical R&D Progressing Toward Predictive Analysis

Pharma R&D is now traversing towards progressive analysis. In this post we have listed top three technologies that will avail the same.

Reddy's Lab acquires injectable portfolio from US-based Eton Pharma for $50 million

Dr. Reddy’s announced that it has acquired a portfolio of branded and generic injectable products from Deer Park, Illinois, based Eton Pharmaceuticals. Under the terms of the agreement, Dr. Reddy’s will pay $5 million upfront in cash, plus contingent

Dr Reddy's Laboratories aims for mergers and acquisitions to climb up ladder

Dr Reddy's Laboratories said it aims to be among the top five drugmakers in India, largely driven by mergers and acquisitions (M&A) of brands, companies and in-licensing deals targeting chronic categories, along with broadening of nutraceutical...

Moderna booster candidate shows strong response against Omicron subvariants

Moderna Inc said on Wednesday that an updated version of its COVID-19 vaccine designed to target the Omicron variant also generated a strong immune response against the fast-spreading Omicron subvariants BA.4 and BA.5, which have gained a foothold..

AstraZeneca India expands its programme on cancer-screening for women in TN

AstraZeneca India, the services division of biopharmaceutical major AstraZeneca, said it has expanded the Ganga Godavari Cancer -Screening Programme to Tamil Nadu, under its corporate social responsibility...

AstraZeneca & Ionis eye U.S. approval after positive trial data

An interim analysis of AstraZeneca and partner Ionis Pharmaceuticals' eplontersen showed the experimental drug met the main goals in a late-stage trial in patients with a rare, fatal disease, the Anglo-Swedish drugmaker said on Tuesday...

© 2025 India Pharma Outlook. All Rights Reserved.